Physician profile
Kshama Garg
NPI 1295806511
$2,314.20
in general payments reported to CMS, 2019-2025
14 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.99 · 2020: $16.18 · 2021: $71.67 · 2022: $121 · 2023: $427 · 2024: $1,059 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,092.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $561.59 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $501.32 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $471.74 | 2022-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $161.20 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Lilly USA, LLC | $156.04 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Stryker Corporation | $117.29 | 2023 | Mako |
| Exact Sciences Corporation | $88.48 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $69.55 | 2023-2025 | Trelegy Ellipta |
| Pfizer INC. | $48.97 | 2020-2024 | |
| Gilead Sciences, INC. | $37.00 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.85 | 2023-2025 | |
| Ucb, INC. | $29.70 | 2024 | Briviact |
| Fisher & Paykel Healthcare INC | $23.95 | 2024 | Fisher & Paykel Healthcare |
| Amgen INC. | $13.52 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kshama Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.